Microbot Medical Inc（MBOT）财务数据MBOTMicrobot Medical Inc

Evaluating the bottom line, Microbot Medical Inc maintains a gross margin of -266.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2567.63%, while the net margin is -2334.85%. These profitability ratios, combined with a Return on Equity (ROE) of -32.91%, provide a clear picture of how effectively MBOT converts its operational activities into shareholder value.

In the context of the broader market, MBOT competes directly with industry leaders such as QUCY and OKYO. With a market capitalization of $74.55M, it holds a significant position in the sector. When comparing efficiency, MBOT's gross margin of -266.80% stands against QUCY's N/A and OKYO's N/A. Such benchmarking helps identify whether Microbot Medical Inc is trading at a premium or discount relative to its financial performance.

The company reported zero revenue in Q1 2026 but achieved $105,000 in Q1 2026 and $241,000 in Q2 2026, showing a positive trend. However, it has a forward P/E of 31.746, indicating high valuation expectations despite losses.